AU2023221847A1 - Inhibitors of nlrp3 - Google Patents
Inhibitors of nlrp3 Download PDFInfo
- Publication number
- AU2023221847A1 AU2023221847A1 AU2023221847A AU2023221847A AU2023221847A1 AU 2023221847 A1 AU2023221847 A1 AU 2023221847A1 AU 2023221847 A AU2023221847 A AU 2023221847A AU 2023221847 A AU2023221847 A AU 2023221847A AU 2023221847 A1 AU2023221847 A1 AU 2023221847A1
- Authority
- AU
- Australia
- Prior art keywords
- disease
- compound
- mmol
- mixture
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263311463P | 2022-02-18 | 2022-02-18 | |
| US63/311,463 | 2022-02-18 | ||
| PCT/US2022/075421 WO2023028534A1 (en) | 2021-08-25 | 2022-08-24 | Inhibitors of nlrp3 |
| AUPCT/US2022/075421 | 2022-08-24 | ||
| PCT/US2023/062771 WO2023159148A2 (en) | 2022-02-18 | 2023-02-16 | Inhibitors of nlrp3 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2023221847A1 true AU2023221847A1 (en) | 2024-09-05 |
Family
ID=87579158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2023221847A Pending AU2023221847A1 (en) | 2022-02-18 | 2023-02-16 | Inhibitors of nlrp3 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20250179078A1 (https=) |
| EP (1) | EP4479045A4 (https=) |
| JP (1) | JP2025509088A (https=) |
| KR (1) | KR20240164495A (https=) |
| CN (2) | CN118302417A (https=) |
| AU (1) | AU2023221847A1 (https=) |
| CA (1) | CA3243870A1 (https=) |
| CL (1) | CL2024002455A1 (https=) |
| CO (1) | CO2024011162A2 (https=) |
| CR (1) | CR20240345A (https=) |
| IL (1) | IL315027A (https=) |
| MX (1) | MX2024010092A (https=) |
| PE (1) | PE20250604A1 (https=) |
| WO (1) | WO2023159148A2 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4362946A4 (en) * | 2021-06-29 | 2025-05-21 | Zomagen Biosciences Ltd | Nlrp3 modulators |
| WO2023051761A1 (zh) * | 2021-09-30 | 2023-04-06 | 成都奥睿药业有限公司 | 一类取代杂芳酞嗪衍生物的药学用途及其制备方法 |
| JP2025524640A (ja) * | 2022-07-14 | 2025-07-30 | エーシー・イミューン・エス・アー | Ｎｌｒｐ３インフラマソーム経路の調節剤としてのピロロトリアジン及びイミダゾトリアジン誘導体 |
| CN120379995A (zh) * | 2022-12-27 | 2025-07-25 | 正大天晴药业集团股份有限公司 | 一种哒嗪稠芳环化合物及其用途 |
| EP4667468A1 (en) | 2023-02-14 | 2025-12-24 | Shenzhen Zhongge Biological Technology Co., Ltd. | Compound for inhibiting nlrp3, preparation method, and use |
| US20250195511A1 (en) * | 2023-12-14 | 2025-06-19 | Merck Sharp & Dohme Llc | Indazole derivatives useful as inhibitors of nod-like receptor protein 3 |
| WO2025133307A1 (en) * | 2023-12-22 | 2025-06-26 | Ac Immune Sa | Heterocyclic modulators of the nlrp3 inflammasome pathway |
| WO2025153532A1 (en) | 2024-01-16 | 2025-07-24 | NodThera Limited | Nlrp3 inhibitors and glp-1 agonists combination therapies |
| WO2026057747A1 (en) | 2024-09-11 | 2026-03-19 | Ac Immune Sa | Therapeutic use of nlrp3 inflammasome pathway inhibitor compounds |
| WO2026067767A1 (zh) * | 2024-09-30 | 2026-04-02 | 普罗思特(南京)生物科技有限公司 | 取代的哒嗪衍生物及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ702611A (en) * | 2012-05-16 | 2016-10-28 | Cellzome Ltd | Substituted 3, 4 - dihydro - 2h - pyrido [1, 2 -a] pyrazine - 1, 6 - dione derivatives useful for the treatment of (inter alia) alzheimer’s disease |
| WO2014007217A1 (ja) * | 2012-07-02 | 2014-01-09 | 大鵬薬品工業株式会社 | イミダゾオキサジン化合物による抗腫瘍効果増強剤 |
| WO2018221433A1 (ja) * | 2017-05-29 | 2018-12-06 | 第一三共株式会社 | ヘテロアリールアミン誘導体 |
| AU2021257619A1 (en) * | 2020-04-15 | 2022-12-15 | Janssen Pharmaceutica Nv | Pyrazolo[1,5-d][1,2,4]triazine-5(4H)-acetamides as inhibitors of the NLRP3 inflammasome pathway |
| EP4362946A4 (en) * | 2021-06-29 | 2025-05-21 | Zomagen Biosciences Ltd | Nlrp3 modulators |
| CR20240093A (es) * | 2021-08-25 | 2024-05-23 | Ptc Therapeutics Inc | Inhibidores de NLRP3 |
| WO2023051761A1 (zh) * | 2021-09-30 | 2023-04-06 | 成都奥睿药业有限公司 | 一类取代杂芳酞嗪衍生物的药学用途及其制备方法 |
-
2022
- 2022-08-24 CN CN202280071320.9A patent/CN118302417A/zh active Pending
-
2023
- 2023-02-16 CN CN202380034776.2A patent/CN119212699A/zh active Pending
- 2023-02-16 AU AU2023221847A patent/AU2023221847A1/en active Pending
- 2023-02-16 US US18/839,229 patent/US20250179078A1/en active Pending
- 2023-02-16 IL IL315027A patent/IL315027A/en unknown
- 2023-02-16 WO PCT/US2023/062771 patent/WO2023159148A2/en not_active Ceased
- 2023-02-16 EP EP23757102.1A patent/EP4479045A4/en active Pending
- 2023-02-16 PE PE2024001809A patent/PE20250604A1/es unknown
- 2023-02-16 CR CR20240345A patent/CR20240345A/es unknown
- 2023-02-16 CA CA3243870A patent/CA3243870A1/en active Pending
- 2023-02-16 KR KR1020247027203A patent/KR20240164495A/ko active Pending
- 2023-02-16 JP JP2024548556A patent/JP2025509088A/ja active Pending
-
2024
- 2024-08-15 CL CL2024002455A patent/CL2024002455A1/es unknown
- 2024-08-16 MX MX2024010092A patent/MX2024010092A/es unknown
- 2024-08-16 CO CONC2024/0011162A patent/CO2024011162A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CO2024011162A2 (es) | 2024-12-09 |
| EP4479045A4 (en) | 2026-03-04 |
| EP4479045A2 (en) | 2024-12-25 |
| CR20240345A (es) | 2024-09-16 |
| CA3243870A1 (en) | 2023-08-24 |
| WO2023159148A3 (en) | 2023-10-05 |
| IL315027A (en) | 2024-10-01 |
| KR20240164495A (ko) | 2024-11-19 |
| WO2023159148A2 (en) | 2023-08-24 |
| MX2024010092A (es) | 2024-12-06 |
| JP2025509088A (ja) | 2025-04-11 |
| US20250179078A1 (en) | 2025-06-05 |
| PE20250604A1 (es) | 2025-02-26 |
| CN118302417A (zh) | 2024-07-05 |
| CN119212699A (zh) | 2024-12-27 |
| CL2024002455A1 (es) | 2025-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4479045A2 (en) | Inhibitors of nlrp3 | |
| AU2022334474A1 (en) | Inhibitors of nlrp3 | |
| JP5121716B2 (ja) | ピリジン誘導体および精神異常の処置におけるそれらの使用 | |
| WO2023028536A1 (en) | 1,2,4-triazine derivatives useful as inhibitors of nlrp3 | |
| CN101243088B (zh) | p38 MAP激酶抑制剂及使用它的方法 | |
| JP2020533376A (ja) | ピラゾロピリミジノン化合物およびその使用 | |
| JP2005529909A (ja) | Ｇａｂａ受容体に対するリガンドとしてのイミダゾ−トリアジン誘導体 | |
| JP2009507801A5 (https=) | ||
| JP2026502905A (ja) | Ｎｌｒｐ３の阻害剤としてのヘテロ環式及びヘテロアリール化合物 | |
| AU2010214101A1 (en) | Histamine H3 inverse agonists and antagonists and methods of use thereof | |
| JP7090036B2 (ja) | 新規な［１，２，３］トリアゾロ［４，５－ｄ］ピリミジン誘導体 | |
| WO2016196417A1 (en) | Dihydropyrazolopyrimidinone compounds as pde2 inhibitors | |
| JP2009506009A (ja) | ｐ３８ＭＡＰキナーゼ阻害剤及びその使用方法 | |
| CN112088003A (zh) | 制备嘧啶基-4-氨基吡唑化合物的工艺 | |
| CN108148060A (zh) | 取代的杂环化合物及其衍生物，其药物组合物、制备方法及用途 | |
| JP2025506422A (ja) | Ｔｒｐａ１阻害剤としてのピリダジノン化合物 | |
| AU2022357572A1 (en) | BICYCLIC AMINE DERIVATIVES AS GABAA α5 RECEPTOR MODULATORS | |
| WO2018109271A1 (en) | New bromodomain inhibitors | |
| CA3186635A1 (en) | Therapeutic agents targeting gpr35 | |
| CN101558072A (zh) | 吡唑并[3,4-d]嘧啶p38map激酶抑制剂 | |
| CA3171441A1 (en) | Naphthyridine and pyrido[3,4-c]pyridazine derivatives as gabaa .alpha_5.receptor modulators | |
| AU2011337041B2 (en) | 3-substituted-6-(pyridinylmethoxy)-pyrrolopyridine compounds | |
| WO2003087099A1 (en) | Imidazo-pyridine derivatives as ligands for gaba receptors | |
| HK40120655A (zh) | 用於治疗神经性病症的杂芳族化合物 | |
| JP2025530734A (ja) | 神経障害の治療のためのヘテロ芳香族化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ ZHANG, XIAOYAN; ALAM, RAUFUL; BEJCEK, LAUREN; GILBERT, BRADLEY B.; HOSSEYNI, SEYEDMORTEZA; HUARTE, EDUARDO; LI, JING; LIU, YAO; NIEDERER, KYLE; PARKER, ERICA N.; PILLAI, MEENU; RASTELLI, ETTORE; SYDORENKO, NADIYA; ZHANG, NANJING; ZHENG, TIANYI; WOLL, MATTHEW G. AND -, HANDOKO |